Intelligent Diabetes Management System with Integrated CGM and Insulin Pump

A wearable or implantable system that combines continuous glucose monitoring (CGM) and insulin pump functionalities with advanced technologies like machine learning, IoT, blockchain, and AI to provide personalized diabetes therapy and improve patient outcomes.

The original patent for automatic detection of un-bolused meals addressed the need for more accurate and controlled fluid delivery in diabetes therapy. However, it relied on user input and did not integrate with other technologies to provide a more comprehensive solution. The new inventive concept builds upon this foundation by incorporating advanced technologies to create a more powerful and autonomous system.

The system consists of a wearable or implantable device that integrates a CGM sensor and an insulin pump. The device uses machine learning algorithms to predict meal times and automatically deliver a meal bolus based on the CGM data. The system communicates with a cloud-based server that utilizes blockchain technology to ensure secure and transparent data storage. The server provides updates on insulin dosing and meal planning, and the system integrates with a mobile application to provide real-time notifications and alerts to the user. The mobile application utilizes natural language processing to provide personalized coaching and support.

The new claims introduce the integration of advanced technologies like machine learning, IoT, blockchain, and AI to create a more autonomous and personalized diabetes management system. This integration provides a new and non-obvious solution that improves patient outcomes and addresses the limitations of the original patent.

Alternative embodiments of the inventive concept could include different form factors, such as a handheld device or a desktop system. Variations could include different machine learning algorithms, alternative communication protocols, or different types of sensors and actuators.

The intelligent diabetes management system has significant commercial potential in the diabetes therapy market, particularly among patients who require frequent insulin dosing and monitoring. The system's ability to provide personalized and autonomous therapy could improve patient outcomes and reduce healthcare costs.